Study protocol and statistical analysis plan for the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial.

2020-06

Poole, Alexis P

Finnis, Mark E

Anstey, James

Bellomo, Rinaldo

Bihari, Shailesh

Biradar, Vishwanath

Doherty, Sarah

Eastwood, Glenn

Finfer, Simon

French, Craig J

Ghosh, Angaj

Heller, Simon

Horowitz, Michael

Kar, Palash

Kruger, Peter S

Maiden, Matthew J

Mårtensson, Johan

McArthur, Colin J

McGuinness, Shay P

Secombe, Paul J

Tobin, Antony E

Udy, Andrew A

Young, Paul J

Deane, Adam M

Journal Article

0000-0002-1650-8939

Contemporary glucose management of intensive care unit (ICU) patients with type 2 diabetes is based on trial data derived predominantly from patients without type 2 diabetes. This is despite the recognition that patients with type 2 diabetes may be relatively more tolerant of hyperglycaemia and more susceptible to hypoglycaemia. It is uncertain whether glucose targets should be more liberal in patients with type 2 diabetes. To detail the protocol, analysis and reporting plans for a randomised clinical trial - the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial - which will evaluate the risks and benefits of targeting a higher blood glucose range in patients with type 2 diabetes. A multicentre, parallel group, open label phase 2B randomised controlled clinical trial of 450 critically ill patients with type 2 diabetes. Patients will be randomised 1:1 to liberal blood glucose (target 10.0-14.0 mmol/L) or usual care (target 6.0-10.0 mmol/L). The primary endpoint is incident hypoglycaemia (< 4.0 mmol/L) during the study intervention. Secondary endpoints include biochemical and feasibility outcomes. The study protocol and statistical analysis plan described will delineate conduct and analysis of the trial, such that analytical and reporting bias are minimised. This trial has been registered on the Australian New Zealand Clinical Trials Registry (ACTRN No. 12616001135404) and has been endorsed by the Australian and New Zealand Intensive Care Society Clinical Trials Group.

link

Critical Care and Resuscitation 2020; 22(2): 133-141

Critical Care and Resuscitation

1441-2772